lilly tirzepatide approval FDA for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly is now pharma's top

In individuals with type 2 diabetes and a heightened risk of cardiovascular events, tirzepatide demonstrated greater and clinically significant reduction in HbA1c compared to glargine at week 52

However, stopping 24 to 48 hours before surgery (rather than the day of) gives your system optimal time to adjust and reduces the risk of gastrointestinal complications during your procedure

The long-term safety profile will not be fully established until larger and longer trials are completed

This is where the concept of synergy comes in

Our GLP-1 friendly shakes contain all of these elements in carefully recommended amounts